Kate Maclagan

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Mild-to-moderate depressive symptoms impact on self-reported outcome measures in clinical trials for neurodegenerative diseases.

Mild-to-moderate depressive symptoms impact on self-reported outcome measures in clinical trials for neurodegenerative diseases.

Journal: Clinical trials (London, England)

Published: December 01, 2025

Exploring Analysis Approaches for Using the Dopamine Transporter Striatal Binding Ratio in Early- to Mid-Stage Parkinson's Disease Modification Trials.

Exploring Analysis Approaches for Using the Dopamine Transporter Striatal Binding Ratio in Early- to Mid-Stage Parkinson's Disease Modification Trials.

Journal: Movement disorders clinical practice

Published: April 10, 2024

Pravastatin Versus Placebo in Pregnancies at High Risk of Term Preeclampsia.

Pravastatin Versus Placebo in Pregnancies at High Risk of Term Preeclampsia.

Journal: Circulation

Published: June 24, 2021

Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson's disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The 'Exenatide-PD3' study.

Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson's disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The 'Exenatide-PD3' study.

Journal: BMJ open

Published: May 29, 2021

Early vaginal progesterone versus placebo in twin pregnancies for the prevention of spontaneous preterm birth: a randomized, double-blind trial.

Early vaginal progesterone versus placebo in twin pregnancies for the prevention of spontaneous preterm birth: a randomized, double-blind trial.

Journal: American journal of obstetrics and gynecology

Published: April 16, 2020

Neprilysin inhibition for pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled, proof-of-concept trial.

Neprilysin inhibition for pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled, proof-of-concept trial.

Journal: British journal of pharmacology

Published: October 25, 2018

What Effects Might Exenatide have on Non-Motor Symptoms in Parkinson's Disease: A Post Hoc Analysis.

What Effects Might Exenatide have on Non-Motor Symptoms in Parkinson's Disease: A Post Hoc Analysis.

Journal: Journal of Parkinson's disease

Published: May 31, 2018

Post hoc analysis of the Exenatide-PD trial-Factors that predict response.

Post hoc analysis of the Exenatide-PD trial-Factors that predict response.

Journal: The European journal of neuroscience

Published: April 30, 2018

Comparison of diagnostic accuracy of early screening for pre-eclampsia by NICE guidelines and a method combining maternal factors and biomarkers: results of SPREE.

Comparison of diagnostic accuracy of early screening for pre-eclampsia by NICE guidelines and a method combining maternal factors and biomarkers: results of SPREE.

Journal: Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology

Published: February 21, 2018

Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia.

Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia.

Journal: The New England journal of medicine

Published: June 29, 2017

Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.

Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.

Journal: Lancet (London, England)

Published: February 21, 2017

Showing 1-11 of 11

Last Updated: 09/26/2026